Literature DB >> 3543359

31P nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites.

V L Boyd, J D Robbins, W Egan, S M Ludeman.   

Abstract

31P NMR spectroscopy was used to directly monitor, for the first time, the intracellular chemistry of the ultimate active metabolite of cyclophosphamide, namely, phosphoramide mustard. These NMR studies utilized a human histiocytic lymphoma cell line (U937), embedded in agarose gel threads, and perfused with medium containing synthetically derived metabolites (4-hydroxycyclophosphamide, aldophosphamide, and phosphoramide mustard). Metabolites 2 or 3 or both readily crossed the cell membrane; in contrast, the membrane was relatively impermeable to 4. Intracellular concentrations of 4 could, therefore, be attributed primarily to the intracellular fragmentation of 3. Signals suggestive of either carboxyphosphamide or 4-ketophosphamide were not detected. Spectral data were used to calculate a rate constant of (5.4 +/- 0.3) X 10(-3) min-1 for the intracellular disappearance of 4 at 23 degrees C. The intracellular pH was determined to be 7.1 from the chemical shift of the internal inorganic phosphate signal.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3543359     DOI: 10.1021/jm00157a015

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

Review 1.  NMR studies of drug metabolism and disposition.

Authors:  J D Bell; D G Gadian; N E Preece
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 2.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  M J Moore
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

3.  Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.

Authors:  Priya P Gor; H Irene Su; Robert J Gray; Phyllis A Gimotty; Michelle Horn; Richard Aplenc; William P Vaughan; Martin S Tallman; Timothy R Rebbeck; Angela DeMichele
Journal:  Breast Cancer Res       Date:  2010-05-10       Impact factor: 6.466

4.  Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients.

Authors:  Gaurav Agarwal; Sonam Tulsyan; Punita Lal; Balraj Mittal
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

Review 5.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

6.  In vivo detection of ifosfamide by 31P-MRS in rat tumours: increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas.

Authors:  L M Rodrigues; R J Maxwell; P M McSheehy; C R Pinkerton; S P Robinson; M Stubbs; J R Griffiths
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Dioscorea bulbifera polysaccharide and cyclophosphamide combination enhances anti-cervical cancer effect and attenuates immunosuppression and oxidative stress in mice.

Authors:  Hongxia Cui; Ting Li; Liping Wang; Yan Su; Cory J Xian
Journal:  Sci Rep       Date:  2016-01-12       Impact factor: 4.379

8.  The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells.

Authors:  Ana Reis-Mendes; Félix Carvalho; Fernando Remião; Emília Sousa; Maria de Lourdes Bastos; Vera Marisa Costa
Journal:  Biomolecules       Date:  2019-03-11

9.  Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.

Authors:  Nobuya Hiraoka; Jiro Kikuchi; Takahiro Yamauchi; Daisuke Koyama; Taeko Wada; Mitsuyo Uesawa; Miyuki Akutsu; Shigehisa Mori; Yuichi Nakamura; Takanori Ueda; Yasuhiko Kano; Yusuke Furukawa
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.